Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Quality of life and supportive care for patients with metastatic renal cell carcinoma.

Lambea J, Hinojo C, Lainez N, Lázaro M, León L, Rodríguez A, Soto de Prado D, Esteban E.

Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S33-9. doi: 10.1007/s10555-012-9357-9. Review.

PMID:
22684341
2.

Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial.

Cella D, Pickard AS, Duh MS, Guerin A, Mishagina N, Antràs L, Neary MP, McCann L, Hodge R, Sternberg CN.

Eur J Cancer. 2012 Feb;48(3):311-23. doi: 10.1016/j.ejca.2011.05.017.

PMID:
21689927
3.

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.

Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ.

BJU Int. 2011 Nov;108(10):1556-63. doi: 10.1111/j.1464-410X.2011.10629.x. Epub 2011 Sep 27. Review.

4.

Assessment of health-related quality of life in Japanese patients with metastatic renal cell carcinoma during treatment with tyrosine kinase inhibitors.

Miyake H, Harada K, Inoue TA, Fujisawa M.

Med Oncol. 2014 Sep;31(9):190. doi: 10.1007/s12032-014-0190-6. Epub 2014 Aug 22.

PMID:
25146670
5.

ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.

Patard JJ, Pignot G, Escudier B, Eisen T, Bex A, Sternberg C, Rini B, Roigas J, Choueiri T, Bukowski R, Motzer R, Kirkali Z, Mulders P, Bellmunt J.

Eur Urol. 2011 Oct;60(4):684-90. doi: 10.1016/j.eururo.2011.06.017. Epub 2011 Jun 24. Review.

PMID:
21704448
6.

Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.

Oudard S, Elaidi RT.

Cancer Treat Rev. 2012 Dec;38(8):981-7. doi: 10.1016/j.ctrv.2011.12.009. Epub 2012 Jan 30. Review.

PMID:
22289686
7.

Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action.

González Larriba JL, Espinosa E, García Carbonero I, García-Donas J, López M, Meana A, Puente J, Bellmunt J.

Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S11-7. doi: 10.1007/s10555-012-9354-z. Review.

PMID:
22674353
8.

Current systemic management of metastatic renal cell carcinoma - first line and second line therapy.

Wright I, Kapoor A.

Curr Opin Support Palliat Care. 2011 Sep;5(3):211-21. doi: 10.1097/SPC.0b013e3283490418. Review.

PMID:
21725244
9.

Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.

Bukowski RM.

Expert Opin Pharmacother. 2010 Oct;11(14):2351-62. doi: 10.1517/14656566.2010.499126. Review.

PMID:
20586712
10.

Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.

Ainsworth NL, Lee JS, Eisen T.

Expert Rev Anticancer Ther. 2009 Dec;9(12):1793-805. doi: 10.1586/era.09.144. Review.

PMID:
19954291
11.

Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy.

Calvo E, Grünwald V, Bellmunt J.

Eur J Cancer. 2014 May;50(7):1321-9. doi: 10.1016/j.ejca.2014.02.007. Epub 2014 Mar 1. Review.

PMID:
24594299
12.

Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib.

Trask PC, Bushmakin AG, Cappelleri JC, Bycott P, Liau K, Kim S.

Acta Oncol. 2008;47(5):843-51. doi: 10.1080/02841860802047395.

PMID:
18568482
13.

Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib.

Casciano R, Chulikavit M, Di Lorenzo G, Liu Z, Baladi JF, Wang X, Robertson J, Garrison L.

Value Health. 2011 Sep-Oct;14(6):846-51. doi: 10.1016/j.jval.2011.04.008. Epub 2011 Jul 28.

14.

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.

Chan HY, Grossman AB, Bukowski RM.

Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Epub 2010 Jul 8. Review.

PMID:
20623346
15.

[Second-line treatment of advanced renal cell carcinoma after first-line targeted therapy].

Tomita Y.

Gan To Kagaku Ryoho. 2011 Jun;38(6):907-10. Japanese.

PMID:
21677480
16.

What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?

Calvo E, Ravaud A, Bellmunt J.

Cancer Treat Rev. 2013 Jun;39(4):366-74. doi: 10.1016/j.ctrv.2012.06.010. Epub 2012 Jul 23. Review.

PMID:
22832091
17.

Targeted therapy in the treatment of metastatic renal cell cancer.

Di Lorenzo G, Scagliarini S, Di Napoli M, Scognamiglio F, Rizzo M, Carteni' G.

Oncology. 2009;77 Suppl 1:122-31. doi: 10.1159/000258504. Epub 2010 Feb 2. Review.

PMID:
20130440
18.

Pazopanib for the treatment of metastatic renal cell carcinoma.

Pick AM, Nystrom KK.

Clin Ther. 2012 Mar;34(3):511-20. doi: 10.1016/j.clinthera.2012.01.014. Epub 2012 Feb 16. Review.

PMID:
22341567
19.

Targeted therapy for renal cell cancer: current perspectives.

van der Veldt AA, Haanen JB, van den Eertwegh AJ, Boven E.

Discov Med. 2010 Nov;10(54):394-405. Review.

20.

Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.

Méndez-Vidal MJ, Martínez Ortega E, Montesa Pino A, Pérez Valderrama B, Viciana R.

Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S19-27. doi: 10.1007/s10555-012-9355-y. Review.

PMID:
22821550

Supplemental Content

Support Center